Indoleamine 2,3 dioxygenase and regulation of T cell immunity
- 8 September 2005
- journal article
- review article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 338 (1) , 20-24
- https://doi.org/10.1016/j.bbrc.2005.08.232
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapyNature Medicine, 2005
- Ido expression by dendritic cells: tolerance and tryptophan catabolismNature Reviews Immunology, 2004
- Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodesJournal of Clinical Investigation, 2004
- Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specificJournal of Reproductive Immunology, 2004
- Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNature Medicine, 2003
- Tolerance, DCs and tryptophan: much ado about IDOTrends in Immunology, 2003
- Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejectionInternational Journal of Cancer, 2002
- Prevention of T cell–driven complement activation and inflammation by tryptophan catabolism during pregnancyNature Immunology, 2001
- Prevention of Allogeneic Fetal Rejection by Tryptophan CatabolismScience, 1998
- Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolismThe FASEB Journal, 1991